Pharmafile Logo

China

- PMLiVE

India’s export curbs raise fears of global drug shortages

Decision comes amid increased concerns over coronavirus outbreak

The ALS patient journey

Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...

Blue Latitude Health

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

Life with multiple myeloma – why I’m a lucky man living the dream

Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling...

Blue Latitude Health

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

- PMLiVE

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

- PMLiVE

China okays Green Valley’s algae-based drug for Alzheimer’s drug

Due to start phase 3 trials in the US and Europe next year

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Research Partnership

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links